Acetylation plays an important role in regulating the chaperone activity of heat shock protein 90 (Hsp90) during malignant transformation through the stabilization and conformational maturation of oncogenic proteins. However, the functional acetylation sites, potential anticancer drug targets, are still emerging. We found that acetylation at K292 in Hsp90α is critical for the development and treatment of breast cancer. Acetylation at K292 not only augments the affinity of Hsp90 to ATP, cochaperones, and client proteins but it also promotes cancer cell colony formation, migration, and invasion in vitro as well as tumor growth in vivo. Importantly, K292-acetylated Hsp90 has been validated as an exciting anticancer drug target by interfering with the complex formation between K292-acetylated Hsp90 and cochaperone Cdc37, leading to diminishment of kinase client maturation and proteasome-dependent degradation of kinase substrates. Furthermore, we showed that simvastatin prevented, whereas LBH589 promoted, the progression of Hsp90 chaperone cycling and client maturation, resulting in an increment of cell apoptosis by the combination of simvastatin and LBH589 in a mouse xenograft model. These data suggest that simvastatin is a novel Hsp90 inhibitor to disrupt the formation of the K292-acetylated Hsp90/Cdc37 complex in triplenegative breast cancer cells. The combination of simvastatin with LBH589 could be used as a novel therapeutic strategy for triple-negative breast cancer. Although many Hsp90 inhibitors are tested as anticancer agents in clinical trials, 2 none of them have been approved due to side-effects or lacking anticancer activity by upregulating other HSPs (eg, Hsp27
2, represents the most aggressive subtype of breast cancer. 8 In TNBC, Hsp90 levels correlate with poor prognosis and drug resistance. 9 Heat shock protein 90 interacts with clients that are important for breast neoplasia and metastasis. [10] [11] [12] Among client proteins, protein kinases are activated and stabilized by Hsp90 in cooperation with the kinase-specific cochaperone Cdc37.
Histone deacetylase inhibitors (HDACi) are approved by the US FDA. 13, 14 Panobinostat (LBH589), a hydroxamic acid-based deacetylase inhibitor, is used to treat multiple myeloma. Combinations of HDACi with other agents are potential therapeutic strategies for solid tumors. 13, [15] [16] [17] Previously, we identified seven hyperacetylated lysine residues in Hsp90α after LBH589 treatment. 6 Interestingly, only acetylation at K292 increases the binding of Hsp90α to ATP.
However, the significance of this in tumorigenesis is unclear. We report here that simvastatin (Sim), 18 an inhibitor of 3-hydroxy 3-methylglutaryl coenzyme A reductase (HMGCR), targets K292-acetylated Hsp90 to abrogate the interaction of Hsp90 with its cochaperones, clients, and the machinery formation of K292-acetylated Hsp90/Cdc37. We also report the combinatory effects of Sim and LBH589 on TNBC in vitro and in vivo.
| MATERIALS AND METHODS

| Plasmids, reagents, and antibodies
Plasmids expressing Flag (F)-Hsp90, K292Q, and K292R mutant were described previously. 6 The following reagents and antibodies were used: Cdc37, 
| Cell culture, transfection, and stable cell lines
MDA-MB-231, MDA-MB-468, MDA-MB-453, HS578T, MCF-10A, and HEK293 cells were cultured as described. 16 Lipofectamine 2000
(Thermo Fisher Scientific) was used for transfection.
| Generation of acetylated K292 Hsp90α antibody
Affinity-purified polyclonal antibody against Ac-K292-hsp90α was generated against peptide QEELNK(Ac)TKPIW containing acetylated K292 (Shanghai Kanwin Biotechnology, Shanghai, China). Wound healing was continued for 36 hours and photographed.
| Colony formation evaluation
| Transwell assay
Transwell chambers were coated with DMEM-diluted Matrigel and MDA-MB-231 cells stably expressing Hsp90 were suspended in serum-free medium, and added to the upper chamber. Medium containing 10% FBS was added to the lower chamber. Twenty-four hours later, the invasive cells that passed through the membrane to the lower surface were fixed and stained with crystal violet, and photographed by light microscope.
| Evaluation of cytotoxicity
Cells were plated in 96-well microplates at a density of 2 × 
| Determination of synergism and antagonism
Cells were plated in 96-well microplates at a density of 2 × 10 4 cells/well followed by treatment with Sim, LBH589, or a combination for 72 hours.
Synergism or antagonism after drug treatments was evaluated using the combination index (CI) method as described. 16 Each CI ratio is the mean value of at least three independent experiments. 
| Immunoprecipitations and immunoblots
| ATP-sepharose binding assay
Cell lysates were affinity precipitated using KinaseBind γ-phosphatelinked ATP resin (Innova Biosciences, Cambridge, UK) at 4°C for 3 hours. After washing three times with the lysis buffer, the resin was pelleted followed by SDS-PAGE analysis.
| Confocal microscopy
For immunofluorescence analysis, MDA-MB-468 cells were fixed in 4% formaldehyde at room temperature for 30 minutes. Cells were permeabilized using 1× PBS containing 0.1% Triton X-100 at room temperature for 20 minutes, were blocked with 1× PBS containing 1% BSA for 1 hour, and were incubated with monoclonal anti-Hsp90α antibody (1:300) and polyclonal anti-Cdc37 antibody (1:300) at room temperature for 2 hours. After washing with 1× PBS, cells were incubated with secondary antibody (1:500 dilution) in the dark for 1 hour and mounted using Vectashield medium (Vector Laboratories, Burlingame, CA, USA) with DAPI.
Images were captured on a Carl Zeiss LSM710 confocal microscope (Jena, Germany).
| Tumor growth analysis in vivo
Exponentially growing MDA-MB-231 cells were harvested and suspended in 1× PBS to a concentration of 5 × 10 7 cells/mL. In vivo studies were carried out as described. 16 To evaluate their survival, mice were kept behind a sanitary barrier in the controlled environment of a pathogen-free animal facility with a 12:12-hour light : dark cycle at 25 ± 1°C and a relative humidity of 40%-70%. The resting animals were then killed. The survival curve of mice was plotted using the Kaplan-Meier method.
| Statistical methods
Data were obtained from three independent experiments, and are presented as mean ± SEM. Statistical analysis was carried out by using Prism 5.0 (La Jolla, CA, USA; Student's t test or one-way ANOVA). Differences in survival time between animals were assessed using the Cox regression model. P < .05 was considered statistically significant, and all P-values were two-sided. 
| K292-acetylated Hsp90α acts as a target for the screening of Hsp90 inhibitor
In tumor cells, Hsp90 is present in a high-affinity conformation in multichaperone complexes. 19 Therefore, we analyzed the binding of K292-acetylated Hsp90 to cochaperones and client proteins. As shown in Figure 3A , K292Q mutant showed increased affinity of Hsp90 with cochaperones Cdc37, HOP, and AHA1, whereas K292R mutant decreased the affinity. Similarly, K292Q mutant remarkably increased whereas K292R mutant compromised the binding of Hsp90 with kinases epidermal growth factor receptor (EGFR), Raf-1, and CDK4, as well as the kinase downstream substrates p-HSF1 and p-eEF2K ( Figure 3B ). Therefore, the binding of Hsp90 with its client and cochaperone was significantly impacted by the acetylation at K292.
Among Hsp90 cochaperones, activation of protein kinase clients is mediated by Hsp90-Cdc37 machinery facilitating the
is an inhibitor of heat shock protein 90 (Hsp90) acetylated at K292. Acetylation status at K292 influences the formation of Hsp90 chaperone machinery (A) and the interaction between Hsp90 and kinase clients (B). Cell lysates from MDA-MB-231 cells stably expressing Flag-tagged Wt, K292Q (KQ), or K292R (KR) mutant of Hsp90α were immunoprecipitated (IP) with M2 beads followed by immunoblotting (IB) with the indicated antibodies. Protein expression levels in cell lysates were detected by western blotting as indicated. C, Schematic model for high throughput screening of Hsp90 inhibitor disrupting the formation of K292-acetylated Hsp90/p-S13 Cdc37 machinery. Complementation-based bioluminescence assay was used to identify small molecules interrupting the interaction of K292Q Hsp90 with S13D Cdc37. D, Distinct inhibitory activity of three structure-related statins on the interaction between K292Q Hsp90 and S13D Cdc37. E, Inhibitory effects of three statins on the interaction between Hsp90α and p-S13 Hsp90. Thus, an SRL-PFAC assay 22 was generated ( Figure 3C ) and 8 hits (Table 1 ) from the LOPAC library (Sigma-Aldrich) of 1280 pharmacologically active compounds were identified to disrupt K292-acetylation mimic Hsp90 (K292Q)/S13 phosphorylation mimic Cdc37 (S13D) interaction in MDA-MB-231 cells. Except cisplatin, the most promising was Mev, an HMGCR reductase inhibitor, that shows synergistic anticancer effects with LBH589. 16 Interestingly, Sim, an analog of Mev, showed a stronger ability to disrupt the complemented RL activity than Mev in a dose-dependent manner, whereas pravastatin did not show any effect ( Figure 3D ). Similar effects have been observed on the interaction between Hsp90 and p-Cdc37 (Figure 3E) , indicating that the disruption of Hsp90/p-Cdc37 by Sim would be independent of the mevalonate signaling pathway.
To explore whether Sim had any effect on Hsp90 binding with ATP, Wt, and LBH589-treated or K292Q mutant of Hsp90 were analyzed for their affinity with ATP. As shown in Figure 3F Previous studies indicated that acetylation of Hsp90 alters the interaction between Hsp90 and its co-chaperone or clients. 6, 7 We observed a progressive increase in K292-acetylated Hsp90 and its affinity with Hsp27, Hsp70, as well as Hsp90 cochaperone Cdc37
and HOP with increasing concentration of LBH589 in a dosedependent manner ( Figure 4E ). This result indicates the significance of acetylation at K292 for Hsp90 chaperone function.
Importantly, LBH589 increased the acetylation at K292 and the affinity of Hsp90 with its cochaperone Cdc37, HOP, Hsp70, and kinase clients EGFR, CDK4, Raf1, and eEF2K, whereas K292 acetylation-deficient Hsp90 did not respond to LBH589 treatment ( Figure 4F ), suggesting that the binding of Hsp90 to its cochaperone and clients depends on acetylated K292. Cdc37 is the most noteworthy cochaperone for its role in the maturation and function of oncogenic kinases. To explore the explicit effect of Sim and LBH589 on Hsp90 function, we tested whether these agents disrupt the Hsp90-Cdc37 interaction in MDA-MB-231 cells. Simvastatin was observed by confocal microscopy to ablate the codistribution signal (yellow) of Hsp90 (red) and Cdc37 (green) compared with LBH589 treatment alone ( Figure 4G ).
To investigate whether K292-acetylated Hsp90 is a direct target of Sim, K292-acetylated and nonacetylated Hsp90 were purified with antibodies against acK292 and Hsp90, respectively, from Flag- (Table S1 ). The CI for proliferation and viability was also measured by using simultaneously half-diluted Sim and/or LBH589, showing significant synergistic effects in all TNBC cell lines (Table S2 ).
To further confirm that the Hsp90 chaperone system could be Table 2 ). These results strongly suggest that the combined treatment would be a potential strategy for TNBC patients.
| DISCUSSION
Triple-negative breast cancer, lacking estrogen receptor, progesterone receptor, or human epidermal growth factor receptor 2 genes, poses a significant clinic challenge with particularly unfavorable prognoses due to the absence of defined molecular targets. Therefore, new therapeutic strategies are needed. In this study, we found that Sim in combination with LBH589 could specifically target TNBC both in vitro and in vivo, via disrupting the formation of K292-acetylated Hsp90/Cdc37 chaperone machinery.
Hsp90 is required for the maturation and function of oncogenic client proteins in oncogenesis and malignant progression. 24 Interruption of Hsp90 chaperone activity would lead to the proteasomal degradation of oncogenic client proteins. 25 However, none of Hsp90 inhibitors have been approved for clinic treatment. Thus, a new approach disrupting Hsp90/Cdc37 complex may represent an effective strategy for cancer treatment. 22, [26] [27] [28] HDAC inhibitors directly promote the acetylation of Hsp90, with destabilization of the ATP-dependent active Hsp90-client protein complex. 5, 6 As a consequence, client proteins are driven to poly-ubiquitination and proteasomal degradation. In this study, we
show that Wt and K292Q mutant of Hsp90 stimulate proliferation and other malignant features significantly in MDA-MB-231 cells.
However, K292R mutant of Hsp90 only obtained mild enhancement of malignant phenotypes, suggesting that Hsp90 is dominantly acetylated at K292 in MDA-MB-231 cells. We also validate this by quantifying Hsp90 and K292-acetylated Hsp90 in paired human breast carcinoma and para-carcinoma tissues ( Figure 1C) . Consequently, we conclude that significantly increased Hsp90 expression and the acetylation at K292 meet the stressed intracellular environment of cancer cells.
Unlike acetylation at K294, 7 acetylation at K292 alone is sufficient to affect the affinity of Hsp90 to ATP ( Figure 3F ), co-chaperone and client proteins ( Figures 4F, 6A ,B,C,D). Point mutation at K292 significantly impacts the binding of Hsp90 to clients and cochaperones, indicating the importance of acetylation at K292 for the formation of Hsp90/cochaperone or Hsp90/client protein complex. In addition, we verified that Sim is a promising Hsp90 inhibitor
